CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced that it has been awarded $733,437 in grants under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants are for three of Epizyme’s drug discovery programs focused on histone methyltransferases (HMTs): DOT1L, EZH2 and WHSC1. HMTs play an important role in regulating transcription of particular groups of genes that are involved in serious diseases, including cancer.
